资料单张
METYPRESOL 125 mg Powder for Injection
METYPRESOL 500 mg Powder for Injection
METYPRESOL 1 g Powder for Injection
INTRAMED METYPRESOL DILUENT (2 mL; 7,5 mL; 15 mL) vial
SCHEDULING STATUS:
S4
PROPRIETARY NAME:
(and dosage form):
METYPRESOL 125 mg Powder for Injection
METYPRESOL 500 mg Powder for Injection
METYPRESOL 1 g Powder for Injection
INTRAMED METYPRESOL DILUENT (2 mL; 7,5 mL; 15 mL) vial
COMPOSITION:
Metypresol 125 mg contains methylprednisolone sodium succinate equivalent to
methylprednisolone
125 mg.
Metypresol 500 mg contains methyl prednisolone sodium succinate equivalent to methylprednisolone 500 mg.
Metypresol 1 g contains methylprednisolone sodium succinate equivalent to methylprednisolone 1 g Intramed
Metypresol Diluent contains Water for Injection 2 mL (7,5 mL; 15 mL).
PHARMACOLOGICAL CLASSIFICATION:
A.21.5.1 Corticosteroids and analogues.
PHARMACOLOGICAL ACTION:
Metypresol is a glucocorticoid with an anti-inflammatory potency of 5 relative to hydrocortisone while its sodium
retaining potency is 0,5 compared with hydrocortisone. It has an intermediate duration of action (12 to 36 hours).
INDICATIONS:
– Serious acute allergic reaction as supplement to primary therapy such as adrenaline.
– Status asthmaticus.
– Cerebral oedema associated with neoplasms.
– Suppression of graft rejection reactions following transplantation.
– Malignant haematologic diseases (e.g. acute lymphoblastic leukaemia) in conjunction with antineoplastic agents.
– Haematologic dyscrasias (e.g. acute autoimmune hemalytic anaemia idiopathic thrombocytopenic purpurea).
CONTRA-INDICATIONS:
– Acute infections including herpes simplex and herpes zoster, ulceration of the eye, varicella, vaccinia.
– Psychoses.
– Peptic ulcer.
– Cushing's syndrome.
– Osteoporosis.
– Severe psychoneuroses.
– Vaccination wit
阅读完整的文件
资料单张 